Compare Cipla with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs NATCO PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA NATCO PHARMA CIPLA/
NATCO PHARMA
 
P/E (TTM) x 23.3 15.6 149.6% View Chart
P/BV x 2.4 3.1 77.8% View Chart
Dividend Yield % 0.7 1.5 46.4%  

Financials

 CIPLA   NATCO PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-19
NATCO PHARMA
Mar-18
CIPLA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs6781,080 62.8%   
Low Rs484671 72.1%   
Sales per share (Unadj.) Rs198.2592.1 33.5%  
Earnings per share (Unadj.) Rs18.5188.4 9.8%  
Cash flow per share (Unadj.) Rs35.0206.3 17.0%  
Dividends per share (Unadj.) Rs3.008.25 36.4%  
Dividend yield (eoy) %0.50.9 54.8%  
Book value per share (Unadj.) Rs186.3833.6 22.4%  
Shares outstanding (eoy) m805.7036.90 2,183.5%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.91.5 198.2%   
Avg P/E ratio x31.44.6 674.7%  
P/CF ratio (eoy) x16.64.2 391.3%  
Price / Book Value ratio x3.11.1 296.8%  
Dividend payout %16.24.4 369.9%   
Avg Mkt Cap Rs m468,03132,311 1,448.5%   
No. of employees `00022.64.8 468.7%   
Total wages/salary Rs m28,5653,256 877.3%   
Avg. sales/employee Rs Th7,053.14,522.5 156.0%   
Avg. wages/employee Rs Th1,261.5674.0 187.2%   
Avg. net profit/employee Rs Th659.11,439.0 45.8%   
INCOME DATA
Net Sales Rs m159,71021,848 731.0%  
Other income Rs m4,766404 1,179.6%   
Total revenues Rs m164,47522,252 739.1%   
Gross profit Rs m30,9739,284 333.6%  
Depreciation Rs m13,263662 2,003.5%   
Interest Rs m1,684154 1,093.7%   
Profit before tax Rs m20,7918,872 234.3%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6951,920 296.6%   
Profit after tax Rs m14,9246,952 214.7%  
Gross profit margin %19.442.5 45.6%  
Effective tax rate %27.421.6 126.6%   
Net profit margin %9.331.8 29.4%  
BALANCE SHEET DATA
Current assets Rs m124,26621,307 583.2%   
Current liabilities Rs m37,7155,920 637.1%   
Net working cap to sales %54.270.4 76.9%  
Current ratio x3.33.6 91.5%  
Inventory Days Days9173 123.7%  
Debtors Days Days95107 89.1%  
Net fixed assets Rs m105,19014,986 701.9%   
Share capital Rs m1,611369 436.7%   
"Free" reserves Rs m148,51130,353 489.3%   
Net worth Rs m150,12330,760 488.0%   
Long term debt Rs m38,3010-   
Total assets Rs m239,63337,151 645.0%  
Interest coverage x13.358.6 22.8%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.6 113.3%   
Return on assets %6.919.1 36.2%  
Return on equity %9.922.6 44.0%  
Return on capital %11.829.3 40.3%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41010,322 556.2%   
Fx outflow Rs m19,0412,978 639.3%   
Net fx Rs m38,3687,343 522.5%   
CASH FLOW
From Operations Rs m16,9114,636 364.8%  
From Investments Rs m-16,687-11,155 149.6%  
From Financial Activity Rs m-3,4876,509 -53.6%  
Net Cashflow Rs m-3,451-18 19,172.8%  

Share Holding

Indian Promoters % 16.0 52.0 30.7%  
Foreign collaborators % 20.8 1.5 1,415.0%  
Indian inst/Mut Fund % 12.2 7.8 155.6%  
FIIs % 23.7 16.6 142.5%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 26.0 100.8%  
Shareholders   161,166 25,395 634.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   VENUS REMEDIES  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 18, 2019 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS